Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1441-1450 of 1,873) with videos related to

Pageof 188
Sort By:
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|April 13, 2025
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
European Journal of Heart Failure|May 16, 2025
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trialJonathan W Cunningham, Brian L Claggett, Muthiah Vaduganathan, et al.
Pilot and Feasibility Studies|April 22, 2022
Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 TrialNiklas Dyrby Johansen, Daniel Modin, Joshua Nealon, et al.
Journal of the American Heart Association|February 23, 2024
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF TrialsAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
European Journal of Heart Failure|June 24, 2022
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failureRiccardo M Inciardi, Matteo Pagnesi, Carlo M Lombardi, et al.
JAMA|October 20, 2020
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical TrialPaul W Armstrong, Carolyn S P Lam, Kevin J Anstrom, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Pageof 188

Showing results (1441-1450 of 1,873) with videos related to

Sort By:
Pageof 188
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|April 13, 2025
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
European Journal of Heart Failure|May 16, 2025
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trialJonathan W Cunningham, Brian L Claggett, Muthiah Vaduganathan, et al.
Pilot and Feasibility Studies|April 22, 2022
Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 TrialNiklas Dyrby Johansen, Daniel Modin, Joshua Nealon, et al.
Journal of the American Heart Association|February 23, 2024
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF TrialsAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.
European Journal of Heart Failure|June 24, 2022
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failureRiccardo M Inciardi, Matteo Pagnesi, Carlo M Lombardi, et al.
JAMA|October 20, 2020
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical TrialPaul W Armstrong, Carolyn S P Lam, Kevin J Anstrom, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Pageof 188